<named-content content-type="genus-species">Escherichia coli</named-content> Sequence Type 131 <italic toggle="yes">H</italic>30 Is the Main Driver of Emerging Extended-Spectrum-β-Lactamase-Producing <named-content content-type="genus-species">E. coli</named-content> at a Tertiary Care Center

ABSTRACT The H30 strain of Escherichia coli sequence type 131 (ST131-H30) is a recently emerged, globally disseminated lineage associated with fluoroquinolone resistance and, via its H30Rx subclone, the CTX-M-15 extended-spectrum beta-lactamase (ESBL). Here, we studied the clonal background and resi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	James R. Johnson, Brian Johnston, Paul Thuras, Bryn Launer, Evgeni V. Sokurenko, Loren G. Miller
Formato:	article
Lenguaje:	EN
Publicado:	American Society for Microbiology 2016
Materias:	Escherichia coli infections ST131 ST131-H30 antimicrobial resistance clonality extended-spectrum β-lactamase Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/9c8329a9895c4a5fb4c8a82b5f1a05c5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9c8329a9895c4a5fb4c8a82b5f1a05c5
record_format	dspace
spelling	oai:doaj.org-article:9c8329a9895c4a5fb4c8a82b5f1a05c52021-11-15T15:22:03Z<named-content content-type="genus-species">Escherichia coli</named-content> Sequence Type 131 <italic toggle="yes">H</italic>30 Is the Main Driver of Emerging Extended-Spectrum-β-Lactamase-Producing <named-content content-type="genus-species">E. coli</named-content> at a Tertiary Care Center10.1128/mSphere.00314-162379-5042https://doaj.org/article/9c8329a9895c4a5fb4c8a82b5f1a05c52016-12-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mSphere.00314-16https://doaj.org/toc/2379-5042ABSTRACT The H30 strain of Escherichia coli sequence type 131 (ST131-H30) is a recently emerged, globally disseminated lineage associated with fluoroquinolone resistance and, via its H30Rx subclone, the CTX-M-15 extended-spectrum beta-lactamase (ESBL). Here, we studied the clonal background and resistance characteristics of 109 consecutive recent E. coli clinical isolates (2015) and 41 historical ESBL-producing E. coli blood isolates (2004 to 2011) from a public tertiary care center in California with a rising prevalence of ESBL-producing E. coli isolates. Among the 2015 isolates, ST131, which was represented mainly by ST131-H30, was the most common clonal lineage (23% overall). ST131-H30 accounted for 47% (8/17) of ESBL-producing, 47% (14/30) of fluoroquinolone-resistant, and 33% (11/33) of multidrug-resistant isolates. ST131-H30 also accounted for 53% (8/14) of dually fluoroquinolone-resistant, ESBL-producing isolates, with the remaining 47% comprised of diverse clonal groups that contributed a single isolate each. ST131-H30Rx, with CTX-M-15, was the major ESBL producer (6/8) among ST131-H30 isolates. ST131-H30 and H30Rx also dominated (46% and 37%, respectively) among the historical ESBL-producing isolates (2004 to 2011), without significant temporal shifts in relative prevalence. Thus, this medical center’s recently emerging ESBL-producing E. coli strains, although multiclonal, are dominated by ST131-H30 and H30Rx, which are the only clonally expanded fluoroquinolone-resistant, ESBL-producing lineages. Measures to rapidly and effectively detect, treat, and control these highly successful lineages are needed. IMPORTANCE The ever-rising prevalence of resistance to first-line antibiotics among clinical Escherichia coli isolates leads to worse clinical outcomes and higher health care costs, thereby creating a need to discover its basis so that effective interventions can be developed. We found that the H30 subset within E. coli sequence type 131 (ST131-H30) is currently, and has been since at least 2004, the main E. coli lineage contributing to key resistance phenotypes—including extended-spectrum-beta-lactamase (ESBL) production, fluoroquinolone resistance, multidrug resistance, and dual ESBL production-plus-fluoroquinolone resistance—at a United States tertiary care center with a rising prevalence of ESBL-producing E. coli isolates. This identifies ST131-H30 as a target for diagnostic tests and preventive measures designed to curb the emergence of multidrug-resistant E. coli isolates and/or to blunt its clinical impact.James R. JohnsonBrian JohnstonPaul ThurasBryn LaunerEvgeni V. SokurenkoLoren G. MillerAmerican Society for MicrobiologyarticleEscherichia coli infectionsST131ST131-H30antimicrobial resistanceclonalityextended-spectrum β-lactamaseMicrobiologyQR1-502ENmSphere, Vol 1, Iss 6 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Escherichia coli infections ST131 ST131-H30 antimicrobial resistance clonality extended-spectrum β-lactamase Microbiology QR1-502
spellingShingle	Escherichia coli infections ST131 ST131-H30 antimicrobial resistance clonality extended-spectrum β-lactamase Microbiology QR1-502 James R. Johnson Brian Johnston Paul Thuras Bryn Launer Evgeni V. Sokurenko Loren G. Miller <named-content content-type="genus-species">Escherichia coli</named-content> Sequence Type 131 <italic toggle="yes">H</italic>30 Is the Main Driver of Emerging Extended-Spectrum-β-Lactamase-Producing <named-content content-type="genus-species">E. coli</named-content> at a Tertiary Care Center
description	ABSTRACT The H30 strain of Escherichia coli sequence type 131 (ST131-H30) is a recently emerged, globally disseminated lineage associated with fluoroquinolone resistance and, via its H30Rx subclone, the CTX-M-15 extended-spectrum beta-lactamase (ESBL). Here, we studied the clonal background and resistance characteristics of 109 consecutive recent E. coli clinical isolates (2015) and 41 historical ESBL-producing E. coli blood isolates (2004 to 2011) from a public tertiary care center in California with a rising prevalence of ESBL-producing E. coli isolates. Among the 2015 isolates, ST131, which was represented mainly by ST131-H30, was the most common clonal lineage (23% overall). ST131-H30 accounted for 47% (8/17) of ESBL-producing, 47% (14/30) of fluoroquinolone-resistant, and 33% (11/33) of multidrug-resistant isolates. ST131-H30 also accounted for 53% (8/14) of dually fluoroquinolone-resistant, ESBL-producing isolates, with the remaining 47% comprised of diverse clonal groups that contributed a single isolate each. ST131-H30Rx, with CTX-M-15, was the major ESBL producer (6/8) among ST131-H30 isolates. ST131-H30 and H30Rx also dominated (46% and 37%, respectively) among the historical ESBL-producing isolates (2004 to 2011), without significant temporal shifts in relative prevalence. Thus, this medical center’s recently emerging ESBL-producing E. coli strains, although multiclonal, are dominated by ST131-H30 and H30Rx, which are the only clonally expanded fluoroquinolone-resistant, ESBL-producing lineages. Measures to rapidly and effectively detect, treat, and control these highly successful lineages are needed. IMPORTANCE The ever-rising prevalence of resistance to first-line antibiotics among clinical Escherichia coli isolates leads to worse clinical outcomes and higher health care costs, thereby creating a need to discover its basis so that effective interventions can be developed. We found that the H30 subset within E. coli sequence type 131 (ST131-H30) is currently, and has been since at least 2004, the main E. coli lineage contributing to key resistance phenotypes—including extended-spectrum-beta-lactamase (ESBL) production, fluoroquinolone resistance, multidrug resistance, and dual ESBL production-plus-fluoroquinolone resistance—at a United States tertiary care center with a rising prevalence of ESBL-producing E. coli isolates. This identifies ST131-H30 as a target for diagnostic tests and preventive measures designed to curb the emergence of multidrug-resistant E. coli isolates and/or to blunt its clinical impact.
format	article
author	James R. Johnson Brian Johnston Paul Thuras Bryn Launer Evgeni V. Sokurenko Loren G. Miller
author_facet	James R. Johnson Brian Johnston Paul Thuras Bryn Launer Evgeni V. Sokurenko Loren G. Miller
author_sort	James R. Johnson
title	<named-content content-type="genus-species">Escherichia coli</named-content> Sequence Type 131 <italic toggle="yes">H</italic>30 Is the Main Driver of Emerging Extended-Spectrum-β-Lactamase-Producing <named-content content-type="genus-species">E. coli</named-content> at a Tertiary Care Center
title_short	<named-content content-type="genus-species">Escherichia coli</named-content> Sequence Type 131 <italic toggle="yes">H</italic>30 Is the Main Driver of Emerging Extended-Spectrum-β-Lactamase-Producing <named-content content-type="genus-species">E. coli</named-content> at a Tertiary Care Center
title_full	<named-content content-type="genus-species">Escherichia coli</named-content> Sequence Type 131 <italic toggle="yes">H</italic>30 Is the Main Driver of Emerging Extended-Spectrum-β-Lactamase-Producing <named-content content-type="genus-species">E. coli</named-content> at a Tertiary Care Center
title_fullStr	<named-content content-type="genus-species">Escherichia coli</named-content> Sequence Type 131 <italic toggle="yes">H</italic>30 Is the Main Driver of Emerging Extended-Spectrum-β-Lactamase-Producing <named-content content-type="genus-species">E. coli</named-content> at a Tertiary Care Center
title_full_unstemmed	<named-content content-type="genus-species">Escherichia coli</named-content> Sequence Type 131 <italic toggle="yes">H</italic>30 Is the Main Driver of Emerging Extended-Spectrum-β-Lactamase-Producing <named-content content-type="genus-species">E. coli</named-content> at a Tertiary Care Center
title_sort	<named-content content-type="genus-species">escherichia coli</named-content> sequence type 131 <italic toggle="yes">h</italic>30 is the main driver of emerging extended-spectrum-β-lactamase-producing <named-content content-type="genus-species">e. coli</named-content> at a tertiary care center
publisher	American Society for Microbiology
publishDate	2016
url	https://doaj.org/article/9c8329a9895c4a5fb4c8a82b5f1a05c5
work_keys_str_mv	AT jamesrjohnson namedcontentcontenttypegenusspeciesescherichiacolinamedcontentsequencetype131italictoggleyeshitalic30isthemaindriverofemergingextendedspectrumblactamaseproducingnamedcontentcontenttypegenusspeciesecolinamedcontentatatertiarycarecenter AT brianjohnston namedcontentcontenttypegenusspeciesescherichiacolinamedcontentsequencetype131italictoggleyeshitalic30isthemaindriverofemergingextendedspectrumblactamaseproducingnamedcontentcontenttypegenusspeciesecolinamedcontentatatertiarycarecenter AT paulthuras namedcontentcontenttypegenusspeciesescherichiacolinamedcontentsequencetype131italictoggleyeshitalic30isthemaindriverofemergingextendedspectrumblactamaseproducingnamedcontentcontenttypegenusspeciesecolinamedcontentatatertiarycarecenter AT brynlauner namedcontentcontenttypegenusspeciesescherichiacolinamedcontentsequencetype131italictoggleyeshitalic30isthemaindriverofemergingextendedspectrumblactamaseproducingnamedcontentcontenttypegenusspeciesecolinamedcontentatatertiarycarecenter AT evgenivsokurenko namedcontentcontenttypegenusspeciesescherichiacolinamedcontentsequencetype131italictoggleyeshitalic30isthemaindriverofemergingextendedspectrumblactamaseproducingnamedcontentcontenttypegenusspeciesecolinamedcontentatatertiarycarecenter AT lorengmiller namedcontentcontenttypegenusspeciesescherichiacolinamedcontentsequencetype131italictoggleyeshitalic30isthemaindriverofemergingextendedspectrumblactamaseproducingnamedcontentcontenttypegenusspeciesecolinamedcontentatatertiarycarecenter
_version_	1718428087273652224

<named-content content-type="genus-species">Escherichia coli</named-content> Sequence Type 131 <italic toggle="yes">H</italic>30 Is the Main Driver of Emerging Extended-Spectrum-β-Lactamase-Producing <named-content content-type="genus-species">E. coli</named-content> at a Tertiary Care Center

Ejemplares similares